{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5","upperLimit":"10","value":"6.8"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"5","value":"1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"441"},{"groupId":"OG001","value":"222"}],"units":"Participants"}],"description":"Response was defined using RECIST v1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined either A) at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LDs or B) complete disappearance of target lesions, with persistence (but not worsening) of 1 or more nontarget lesions. In either case, no new lesions may have appeared. The percentage of participants with CR or PR=(Number of participants with CR or PR)/(Number of participants assessed)\\*100.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pemetrexed: 500 mg/m\\^2, IV administration, q 21 days, until disease progression.\n\nBSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.","id":"OG000","title":"Pemetrexed and BSC"},{"description":"Placebo: IV administration, q 21 days.\n\nBSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.","id":"OG001","title":"Placebo and BSC"}],"paramType":"NUMBER","populationDescription":"Participants who signed the ICF and completed the randomized process are reported according to the treatment arm to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Baseline to measured PD (up to 41 months)","title":"Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}